A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash in Subjects With Neoplasm Receiving EGFRi or MEKi Therapy
Latest Information Update: 11 Jan 2023
At a glance
- Drugs Imsidolimab (Primary)
- Indications Acneiform eruptions
- Focus Therapeutic Use
- Acronyms EMERGE
- Sponsors AnaptysBio
- 19 Sep 2022 Status changed from recruiting to discontinued.
- 10 Feb 2022 This trial has been completed in Hungary (End Date: 13 Dec 2021), according to European Clinical Trials Database record.
- 22 Dec 2021 This trial has been discontinued in Poland, according to European Clinical Trials Database record.